AGTC - Applied Genetic Technologies Corporation Stock Price, News & Analysis

$3.85 0.05 (1.32 %)
(As of 11/23/2017 04:10 AM ET)
Previous Close$3.80
Today's Range$3.75 - $4.00
52-Week Range$3.25 - $10.15
Volume81,900 shs
Average Volume168,254 shs
Market Capitalization$69.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56

About Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Applied Genetic Technologies Corporation logoApplied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AGTC
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio5.71%
Quick Ratio5.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.47 million
Price / Sales1.76
Cash Flow$0.07 per share
Price / Cash52.18
Book Value$6.38 per share
Price / Book0.60

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($0.26)
Net Income$400,000.00
Net Margins-8.78%
Return on Equity-2.86%
Return on Assets-2.18%

Miscellaneous

Employees72
Outstanding Shares18,090,000

Frequently Asked Questions for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

What is Applied Genetic Technologies Corporation's stock symbol?

Applied Genetic Technologies Corporation trades on the NASDAQ under the ticker symbol "AGTC."

How were Applied Genetic Technologies Corporation's earnings last quarter?

Applied Genetic Technologies Corporation (NASDAQ:AGTC) released its quarterly earnings results on Wednesday, September, 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.22 by $0.40. The biotechnology company earned $8.30 million during the quarter, compared to analyst estimates of $12.39 million. Applied Genetic Technologies Corporation had a negative return on equity of 2.86% and a negative net margin of 8.78%. The company's revenue was down 31.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.15 EPS. View Applied Genetic Technologies Corporation's Earnings History.

When will Applied Genetic Technologies Corporation make its next earnings announcement?

Applied Genetic Technologies Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Applied Genetic Technologies Corporation.

Where is Applied Genetic Technologies Corporation's stock going? Where will Applied Genetic Technologies Corporation's stock price be in 2017?

6 brokerages have issued 1-year price objectives for Applied Genetic Technologies Corporation's shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Applied Genetic Technologies Corporation's stock price to reach $10.17 in the next twelve months. View Analyst Ratings for Applied Genetic Technologies Corporation.

What are Wall Street analysts saying about Applied Genetic Technologies Corporation stock?

Here are some recent quotes from research analysts about Applied Genetic Technologies Corporation stock:

  • 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (10/31/2017)
  • 2. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017)
  • 3. Rodman & Renshaw analysts commented, "A leader in AAV development; first-in-man data soon and critical to investment case. AGTC's AAV (adeno-associated virus) platform is based on a proprietary viral composition and manufacturing process that are backed by strong intellectual property positions. AGTC has the capability to target specific tissue types and drive gene expression appropriate for that tissue. We believe that there is great potential to treat an array of disorders that are monogenic (single gene) and autosomal recessive or X-linked. The company is currently targeting orphan ophthalmological indications with the goal of addressing the underlying biology of the disorder.Plenty of cash to fund development. We believe the preclinical data in hand support our projected outcome for positive results from the ongoing clinical programs. We are quickly approaching critical first-in-man data in mid-2017 from the company's lead program in XLRS and initial clinical data from the ACHM program by year-end 2017. We believe these data should help correct the valuation disconnect we call to investors' attention where the stock is trading below the company's cash balance, primarily due to the early stage nature of the platform. Additionally, the company has approximately two years of cash on hand to deliver to our development projections; furthermore, the trajectory should create inflection points that include the clinical data points mentioned as well as advancing more products into development." (3/15/2017)

Who are some of Applied Genetic Technologies Corporation's key competitors?

Who are Applied Genetic Technologies Corporation's key executives?

Applied Genetic Technologies Corporation's management team includes the folowing people:

  • Scott Koenig M.D., Ph.D., Chairman of the Board (Age 64)
  • Susan B. Washer, President, Chief Executive Officer, Director (Age 55)
  • William A. Sullivan, Chief Financial Officer (Age 46)
  • Jeffrey D. Chulay M.D., Senior Vice President, Chief Medical Officer (Age 70)
  • Mark Shearman Ph.D., Chief Scientific Officer (Age 55)
  • Stephen B. Potter, Vice president and chief business officer (Age 60)
  • Andrew D. Ashe, General Counsel (Age 49)
  • Michael H. Goldstein M.D., Chief Medical Officer (Age 50)
  • David R. Guyer M.D., Director (Age 57)
  • Ivana Magovcevic-Liebisch Ph.D. J.D., Director (Age 49)

Who owns Applied Genetic Technologies Corporation stock?

Applied Genetic Technologies Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (2.18%), ClariVest Asset Management LLC (0.55%), Citadel Advisors LLC (0.23%) and Nine Chapters Capital Management LLC (0.16%). Company insiders that own Applied Genetic Technologies Corporation stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies Corporation.

Who bought Applied Genetic Technologies Corporation stock? Who is buying Applied Genetic Technologies Corporation stock?

Applied Genetic Technologies Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Citadel Advisors LLC, Nine Chapters Capital Management LLC and ClariVest Asset Management LLC. Company insiders that have bought Applied Genetic Technologies Corporation stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies Corporation.

How do I buy Applied Genetic Technologies Corporation stock?

Shares of Applied Genetic Technologies Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Applied Genetic Technologies Corporation's stock price today?

One share of Applied Genetic Technologies Corporation stock can currently be purchased for approximately $3.85.

How big of a company is Applied Genetic Technologies Corporation?

Applied Genetic Technologies Corporation has a market capitalization of $69.66 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Applied Genetic Technologies Corporation employs 72 workers across the globe.

How can I contact Applied Genetic Technologies Corporation?

Applied Genetic Technologies Corporation's mailing address is 14193 Nw 119Th Terrace, Suite #10, ALACHUA, FL 32615, United States. The biotechnology company can be reached via phone at +1-386-4622204.


MarketBeat Community Rating for Applied Genetic Technologies Corporation (AGTC)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $10.17 (164.07% upside)

Consensus Price Target History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Price Target History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Analysts' Ratings History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017WedbushReiterated RatingOutperform$9.00N/AView Rating Details
11/8/2017HC WainwrightReiterated RatingBuy$8.00N/AView Rating Details
10/6/2017Cantor FitzgeraldSet Price TargetHold$9.00N/AView Rating Details
9/14/2017BMO Capital MarketsReiterated RatingOutperform$14.00 -> $7.00HighView Rating Details
9/14/2017Stifel NicolausLower Price TargetBuy -> Buy$15.00 -> $12.00HighView Rating Details
3/15/2017Rodman & RenshawInitiated CoverageBuy -> Buy$16.00HighView Rating Details
11/9/2016Roth CapitalUpgradeNeutral -> Buy$12.00 -> $15.00N/AView Rating Details
9/26/2016Janney Montgomery ScottUpgradeSell -> Neutral$11.00N/AView Rating Details
9/13/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
1/10/2016Chardan CapitalReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Earnings by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Earnings History by Quarter for Applied Genetic Technologies Corporation (NASDAQ AGTC)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018N/AView Earnings Details
9/13/2017Q4 2017$0.22($0.18)$12.39 million$8.30 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.01)($0.05)$10.39 million$8.39 millionViewN/AView Earnings Details
2/8/2017Q217$0.02$0.11$11.10 million$10.90 millionViewListenView Earnings Details
11/8/2016Q117($0.10)$0.20$10.21 million$11.80 millionViewListenView Earnings Details
9/12/2016Q416$0.07$0.15$13.10 million$12.10 millionViewListenView Earnings Details
5/9/2016Q3$0.05$0.11$12.98 million$12.00 millionViewN/AView Earnings Details
2/8/2016Q216($0.19)$0.17$8.76 million$12.20 millionViewN/AView Earnings Details
11/5/2015Q1($0.20)($0.53)$5.91 million$11.06 millionViewN/AView Earnings Details
9/10/2015Q415($0.41)($0.48)$0.63 million$0.71 millionViewN/AView Earnings Details
5/11/2015Q315($0.33)($0.38)$0.59 million$0.28 millionViewN/AView Earnings Details
2/11/2015Q215($0.39)($0.28)$0.45 million$0.65 millionViewN/AView Earnings Details
11/12/2014Q115($0.29)($0.34)$258.00 million$705.00 millionViewN/AView Earnings Details
9/26/2014Q414($0.29)($0.32)$0.23 million$0.12 millionViewN/AView Earnings Details
5/14/2014Q114($0.37)($25.45)$0.15 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
2017 EPS Consensus Estimate: ($0.36)
2018 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.45)$0.09($0.18)
Q2 20172($0.04)($0.02)($0.03)
Q3 20172($0.14)$0.04($0.05)
Q4 20172($0.16)($0.04)($0.10)
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.73)($0.73)($0.73)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Applied Genetic Technologies Corporation (NASDAQ AGTC)

Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 53.02%
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)
Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Insider Trades by Quarter for Applied Genetic Technologies Corporation (NASDAQ AGTC)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Ivana MagovcevicDirectorBuy3,000$9.63$28,890.00View SEC Filing  
11/1/2016Jeffrey D ChulayVPSell1,000$7.05$7,050.00View SEC Filing  
9/22/2016Mark S ShearmanInsiderBuy3,000$8.87$26,610.00View SEC Filing  
9/20/2016Stephen W PotterInsiderBuy1,400$8.89$12,446.00View SEC Filing  
9/19/2016Lawrence E BullockCFOBuy10,000$8.75$87,500.00View SEC Filing  
2/23/2015Plc GlaxosmithklineMajor ShareholderSell503,150$22.00$11,069,300.00View SEC Filing  
1/23/2015Daniel L MenichellaVPSell1,996$24.90$49,700.40View SEC Filing  
12/22/2014Daniel L MenichellaVPSell9,000$20.83$187,470.00View SEC Filing  
4/1/2014Interwest Partners Viii LpMajor ShareholderBuy75,376$12.00$904,512.00View SEC Filing  
4/1/2014Jill CarrollDirectorBuy103,762$12.00$1,245,144.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Applied Genetic Technologies Corporation (NASDAQ AGTC)

Source:
DateHeadline
ETFs with exposure to Applied Genetic Technologies Corp. : November 20, 2017ETFs with exposure to Applied Genetic Technologies Corp. : November 20, 2017
finance.yahoo.com - November 20 at 5:07 PM
$10.92 Million in Sales Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter$10.92 Million in Sales Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - November 16 at 8:38 PM
Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q1, 2018 By the Numbers : November 15, 2017Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q1, 2018 By the Numbers : November 15, 2017
finance.yahoo.com - November 16 at 10:52 AM
-$0.09 Earnings Per Share Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter-$0.09 Earnings Per Share Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - November 14 at 1:28 AM
Brokers Set Expectations for Applied Genetic Technologies Corporations Q3 2018 Earnings (AGTC)Brokers Set Expectations for Applied Genetic Technologies Corporation's Q3 2018 Earnings (AGTC)
www.americanbankingnews.com - November 13 at 7:54 AM
Applied Genetic Technologies Corporation (AGTC) & Its Competitors Critical ComparisonApplied Genetic Technologies Corporation (AGTC) & Its Competitors Critical Comparison
www.americanbankingnews.com - November 11 at 5:28 AM
Q2 2018 EPS Estimates for Applied Genetic Technologies Corporation Decreased by Analyst (AGTC)Q2 2018 EPS Estimates for Applied Genetic Technologies Corporation Decreased by Analyst (AGTC)
www.americanbankingnews.com - November 10 at 11:54 AM
ETFs with exposure to Applied Genetic Technologies Corp. : November 9, 2017ETFs with exposure to Applied Genetic Technologies Corp. : November 9, 2017
finance.yahoo.com - November 9 at 4:40 PM
Applied Genetic Technologies Corporations (AGTC) Buy Rating Reiterated at HC WainwrightApplied Genetic Technologies Corporation's (AGTC) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 8 at 11:10 PM
Edited Transcript of AGTC earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of AGTC earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 8 at 5:49 PM
Applied Genetic Technologies Corporation (AGTC) Stock Rating Reaffirmed by WedbushApplied Genetic Technologies Corporation (AGTC) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - November 8 at 3:40 PM
Applied Genetic Technologies (AGTC) CEO Sue Washer on Q1 2018 Results - Earnings Call Transcript - Seeking AlphaApplied Genetic Technologies' (AGTC) CEO Sue Washer on Q1 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 3:19 AM
Applied Genetic Technologies Corporation (AGTC) Posts Quarterly  Earnings Results, Beats Estimates By $0.06 EPSApplied Genetic Technologies Corporation (AGTC) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - November 8 at 12:22 AM
Applied Genetic Technologies posts 1Q lossApplied Genetic Technologies posts 1Q loss
finance.yahoo.com - November 7 at 10:18 PM
Is Applied Genetic Technologies Corporation (AGTC) A Sell At Its Current Price?Is Applied Genetic Technologies Corporation (AGTC) A Sell At Its Current Price?
finance.yahoo.com - November 7 at 10:18 PM
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 - GlobeNewswire (press release)AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017 - GlobeNewswire (press release)
globenewswire.com - November 7 at 5:15 PM
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2017
finance.yahoo.com - November 7 at 5:14 PM
Applied Genetic Technologies Corporation (AGTC) Receives Average Recommendation of "Hold" from BrokeragesApplied Genetic Technologies Corporation (AGTC) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 12:02 PM
Applied Genetic Technologies Corporation (AGTC) Set to Announce Quarterly Earnings on TuesdayApplied Genetic Technologies Corporation (AGTC) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:58 AM
Applied Genetic Technologies Corporation (AGTC) Cut to Strong Sell at Zacks Investment ResearchApplied Genetic Technologies Corporation (AGTC) Cut to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - October 31 at 5:32 PM
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017 - GlobeNewswire (press release)AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017 - GlobeNewswire (press release)
globenewswire.com - October 31 at 4:52 PM
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017 - GlobeNewswire (press release)AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017 - GlobeNewswire (press release)
globenewswire.com - October 31 at 4:52 PM
AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 7, 2017
finance.yahoo.com - October 31 at 4:52 PM
ETFs with exposure to Applied Genetic Technologies Corp. : October 27, 2017ETFs with exposure to Applied Genetic Technologies Corp. : October 27, 2017
finance.yahoo.com - October 27 at 5:47 PM
Applied Genetic Technologies Corporation (AGTC) Expected to Announce Quarterly Sales of $7.83 MillionApplied Genetic Technologies Corporation (AGTC) Expected to Announce Quarterly Sales of $7.83 Million
www.americanbankingnews.com - October 26 at 11:04 AM
Applied Genetic Technologies Corporation (AGTC) & Its Peers Financial ComparisonApplied Genetic Technologies Corporation (AGTC) & Its Peers Financial Comparison
www.americanbankingnews.com - October 21 at 12:26 AM
ETFs with exposure to Applied Genetic Technologies Corp. : October 16, 2017ETFs with exposure to Applied Genetic Technologies Corp. : October 16, 2017
finance.yahoo.com - October 16 at 4:29 PM
Applied Genetic Technologies Corporation (AGTC) Receives Consensus Recommendation of "Buy" from AnalystsApplied Genetic Technologies Corporation (AGTC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 8 at 9:10 AM
Applied Genetic Technologies Corporation (AGTC) PT Set at $9.00 by Cantor FitzgeraldApplied Genetic Technologies Corporation (AGTC) PT Set at $9.00 by Cantor Fitzgerald
www.americanbankingnews.com - October 6 at 8:34 PM
AGTC and the Medical College of Wisconsin Announce Publication ... - GlobeNewswire (press release)AGTC and the Medical College of Wisconsin Announce Publication ... - GlobeNewswire (press release)
globenewswire.com - October 6 at 3:55 PM
AGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated AchromatopsiaAGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated Achromatopsia
finance.yahoo.com - October 6 at 3:55 PM
-$0.18 EPS Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter-$0.18 EPS Expected for Applied Genetic Technologies Corporation (AGTC) This Quarter
www.americanbankingnews.com - October 5 at 2:08 PM
Earnings Review and Free Research Report: Applied Genetic Announced Q4 and Full Year FY17 ResultsEarnings Review and Free Research Report: Applied Genetic Announced Q4 and Full Year FY17 Results
finance.yahoo.com - October 2 at 3:29 PM
ETFs with exposure to Applied Genetic Technologies Corp. : October 2, 2017ETFs with exposure to Applied Genetic Technologies Corp. : October 2, 2017
finance.yahoo.com - October 2 at 3:29 PM
AGTC to Present at Upcoming Gene Therapy Conferences - GlobeNewswire (press release)AGTC to Present at Upcoming Gene Therapy Conferences - GlobeNewswire (press release)
globenewswire.com - October 1 at 8:53 AM
AGTC to Present at Upcoming ConferencesAGTC to Present at Upcoming Conferences
finance.yahoo.com - September 20 at 3:30 PM
ETFs with exposure to Applied Genetic Technologies Corp. : September 19, 2017ETFs with exposure to Applied Genetic Technologies Corp. : September 19, 2017
finance.yahoo.com - September 19 at 8:43 PM
Applied Genetic Technologies Corporation (AGTC)Applied Genetic Technologies Corporation (AGTC)
finance.yahoo.com - September 18 at 9:06 PM
Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: 2017 By the Numbers : September 18, 2017Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 4:04 PM
Q1 2018 EPS Estimates for Applied Genetic Technologies Corporation (AGTC) Cut by AnalystQ1 2018 EPS Estimates for Applied Genetic Technologies Corporation (AGTC) Cut by Analyst
www.americanbankingnews.com - September 18 at 4:30 AM
Applied Genetic Technologies Corporation (AGTC) Expected to Post Quarterly Sales of $7.83 MillionApplied Genetic Technologies Corporation (AGTC) Expected to Post Quarterly Sales of $7.83 Million
www.americanbankingnews.com - September 18 at 1:40 AM
Applied Genetic Technologies Corporation (AGTC) PT Lowered to $9.00Applied Genetic Technologies Corporation (AGTC) PT Lowered to $9.00
www.americanbankingnews.com - September 16 at 9:04 PM
Wedbush Comments on Applied Genetic Technologies Corporations FY2022 Earnings (AGTC)Wedbush Comments on Applied Genetic Technologies Corporation's FY2022 Earnings (AGTC)
www.americanbankingnews.com - September 15 at 4:52 PM
HC Wainwright Reiterates Buy Rating for Applied Genetic Technologies Corporation (AGTC)HC Wainwright Reiterates Buy Rating for Applied Genetic Technologies Corporation (AGTC)
www.americanbankingnews.com - September 14 at 12:28 PM
BMO Capital Markets Reiterates Outperform Rating for Applied Genetic Technologies Corporation (AGTC)BMO Capital Markets Reiterates Outperform Rating for Applied Genetic Technologies Corporation (AGTC)
www.americanbankingnews.com - September 14 at 9:35 AM
Applied Genetic Technologies Corporation (AGTC) PT Lowered to $12.00Applied Genetic Technologies Corporation (AGTC) PT Lowered to $12.00
www.americanbankingnews.com - September 14 at 9:34 AM
AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30,AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30,
www.nasdaq.com - September 13 at 9:45 PM
Applied Genetic Technologies (AGTC) CEO Sue Washer on Q4 2017 Results - Earnings Call TranscriptApplied Genetic Technologies' (AGTC) CEO Sue Washer on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - September 13 at 9:45 PM
Applied Genetic Technologies Corp. (AGTC) PT Lowered to $12 at StifelApplied Genetic Technologies Corp. (AGTC) PT Lowered to $12 at Stifel
www.streetinsider.com - September 13 at 9:45 PM
Edited Transcript of AGTC earnings conference call or presentation 13-Sep-17 12:00pm GMTEdited Transcript of AGTC earnings conference call or presentation 13-Sep-17 12:00pm GMT
finance.yahoo.com - September 13 at 9:45 PM

Social Media

Financials

Chart

Applied Genetic Technologies Corporation (NASDAQ AGTC) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.